Evaluating neuronal damage biomarkers at birth for predicting neurodevelopmental risks in foetal growth restriction

Mª José Benítez-Marín1,2,3, Marta Blasco-Alonso1,2,4, Fernando de Rodríguez de Fonseca5,6

  • 1Research Group in Maternal-Fetal Medicine, Epigenetics, Women's Diseases and Reproductive Health, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand, Málaga, Spain.

Insights

Biomarkers like urinary S100B and nerve growth factor show potential for predicting neurodevelopmental outcomes in infants with foetal growth restriction. Further research is needed to refine these predictive models.

Area of Science:

  • Neuroscience
  • Developmental Pediatrics
  • Biomarker Research

Background:

  • Foetal growth restriction (FGR) poses significant risks to neurodevelopmental outcomes.
  • Predictive tools for identifying at-risk infants are crucial for timely intervention.
  • Existing research on neural injury biomarkers in FGR requires systematic evaluation.

Purpose of the Study:

  • To systematically review the correlation between biomarkers of neural injury in children with foetal growth restriction and their neurodevelopmental outcomes.
  • To identify potential biomarkers for predicting neurodevelopmental trajectories in FGR.
  • To synthesize current evidence on the association between specific biomarkers and neurodevelopment in FGR.

Main Methods:

  • Systematic review adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
  • Searched PubMed and Embase for studies published between January 2014 and March 2024.
  • Included studies measuring postpartum brain injury biomarkers and assessing childhood neurodevelopment in foetal growth-restricted infants.

Main Results:

  • Five studies met inclusion criteria.
  • Elevated urinary S100B levels in FGR correlated negatively with early neurological development.
  • Neuron-specific enolase showed negative correlations with cognitive, motor, and socio-emotional development.
  • Lower urinary nerve growth factor levels in neonates with FGR were associated with poorer neurodevelopment.
  • Tau protein levels were lower in children with FGR and adverse outcomes; BDNF levels showed no significant alterations.

Conclusions:

  • Specific biomarkers, including urinary S100B, neuron-specific enolase, and nerve growth factor, show promise in predicting neurodevelopmental outcomes in foetal growth restriction.
  • Further research is essential to validate these biomarkers and develop robust predictive models.
  • Understanding these biomarker associations can inform targeted interventions for infants with FGR.
Abstract

Related Concept Videos